RNAi-combined nano-chemotherapeutics to tackle resistant tumors
The merger of nanotechnology and combination chemotherapy has shown notable promise in the therapy of resistant tumors. The latest scientific attention encompasses the engagement of anticancer drugs in combination with small interfering (si)RNAs, such as VEGF, XLAP, PGP, MRP-1, BCL-2 and cMyc, to name but a few. siRNAs have shown immense promise to knockout drug resistance genes as well as to recover the sensitivity of resistant tumors to anticancer therapy. The nanotechnology approach could also protect siRNA against RNAse degradation as well as prevent off-target effects. In this article, we discuss the approaches that have been used to deliver of siRNA in combination with chemotherapeutic drugs to treat resistant tumors. We also discuss the stipulations that must be considered in formulating a nanotechnology-assisted siRNA-drug cancer therapy.
Citation : Tekade, R.K. et al. (2016) RNAi-combined nano-chemotherapeutics to tackle resistant tumors. Drug Discovery Today, in press http://dx.doi.org/10.1016/j.drudis.2016.06.029
ISSN : 1359-6446
Research Group : Pharmaceutical Technologies
Peer Reviewed : Yes
- Leicester School of Pharmacy